摘要
目的 探讨甘精胰岛素联合阿卡波糖对2型糖尿病患者血糖达标率及胰岛β细胞功能的影响.方法 选择2型糖尿病患者70例,按就诊病历号顺序随机分为观察组与对照组.两组患者均予以饮食控制和体育锻炼等基础治疗.观察组在此基础上予以甘精胰岛素联合阿卡波糖治疗,对照组在此基础上予以精蛋白生物合成人胰岛素（预混胰岛素诺和灵30R）治疗,两组疗程均为8周.结果 治疗8周后,观察组患者空腹血糖、餐后2h血糖和糖化血红蛋白的达标率（95.0％、85.0％和77.5％）明显高于对照组（77.5％、62.5％和55.0％）（x2=5.16、5.23和4.53,均P＜0.05）；两组患者空腹C肽及餐后C肽水平均较前明显上升（t=2.43、2.32、2.28、2.19,均P＜0.05）,且观察组上升幅度与对照组比较更明显（t=2.17、2.13,均P＜0.05）.观察组治疗期间低血糖事件的发生率明显低于对照组（x2 =4.11,P＜0.05）.结论 甘精胰岛素联合阿卡波糖治疗2型糖尿病有利于患者的血糖及糖化血红蛋白的达标,减少低血糖事件发生率；同时能更好地保护与改善胰岛β细胞功能,延缓患者减少急慢性并发症的发生和发展.
Objective To explore the effect of insulin glargine combined with carbose onblood glucose attaining standard and pancreatic β cell function of type 2 diabetic patients.Methods 70 type 2 diabetic patients were divided into observation group and control group.All the patients got fundamental treatment as diet control and physical exercise.Patients of observing group got extra treatment as using insulin glargine combined with carbose,while patients of control group got extra treatment as using premixed insulin 30R（isophane protamine biosynthetic human insulin）,all the treatment lasted for 8 weeks.Results 8 weeks after treatment,the rate of reaching standard of FBG and 2h postprandial plasma glucose and glycosylated hemoglobin （95.0%,85.0% and 77.5%） of observing group were significantly higher than those of control group （77.5%,62.5% and 55.0%） （x2 =5.16,5.23 and 4.53,all P 〈0.05）.The levels of FCP and PCP increased significantly in both groups than that of before treatment （t =2.43,2.32,2.28,2.19,all P 〈 0.05）,and the change of observation group was more obviously than that of control group （t =2.17,2.13,all P 〈 0.05）.The occurrence rate of hypoglycemia of observation group was significantly lower than that of control group（x2 =4.11,P 〈0.05）.Conclusion Treating diabetic patient by insulin glargine combined with acarbose has high safety,and helps to reach the standard of FBG and glycosylated hemoglobin,reduce the incurrence rate of hypoglycemia,protect and improve the function of pancreatic 3 cell,and postpone the beginning and progress of complication.
出处
《中国基层医药》
CAS
2013年第19期2960-2962,共3页
Chinese Journal of Primary Medicine and Pharmacy
